Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...

CHICAGO -- SGLT2 inhibitor use was linked to reduced progression of in-situ pulmonary adenocarcinoma, an observational study showed. Nodule growth over the median 28 months of follow-up was 62% less ...

It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung ...

Spatial maps of lung precancer and cancer cells at different points in development advance understanding of the earliest stages of lung cancer Findings highlight inflammation as a driver of lung tumor ...

In this video, Lukas Delasos, DO, an associate staff member of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute, discusses results from the HARMONi trial ...

As a nonsmoker lung cancer hasn't been a concern of mine, but I recently heard it can affect people who have never smoked. If ...